Please assess the completion status of the following clinical trial:

Trial Title: DPP-4 Inhibition and TZD for DM Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Impaired glucose tolerance (IGT) by oral glucose tolerance test~Exclusion Criteria:~* History of diabetes mellitus~* History of congestive heart failure~* History of coronary artery disease or other macrovascular disease (stroke, peripheral vascular disease)~* History of liver disease (ALT or AST \>2.5 times the upper limit of normals)~* History of renal disease (serum creatinine \>1.5 mg/dl)~* History of severe osteoporosis (frequent fractures, failure on osteoporosis treatment)~* Current treatment with glucocorticoids~* History of immune disorder, including HIV~* Women of child-bearing age who are pregnant, desire to become pregnant, are breastfeeding, or who refuse to take the recommended birth control measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Sitagliptin + Pioglitazone PLACEBO (Type: EXPERIMENTAL): Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth
- Sitagliptin + Pioglitazone (Type: EXPERIMENTAL): Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth
- PLACEBO (Type: PLACEBO_COMPARATOR): Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).